Acute megakaryoblastic leukemia developing as donor cell leukemia after umbilical cord blood transplantation

6Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

A 64-year-old man with acute myeloid leukemia underwent umbilical cord blood transplantation (UCBT). After 11 months of complete remission (CR) following UCBT, the bone marrow showed 7.5% myeloblasts. CR was obtained after a single course of azacitidine mono therapy, but the myeloblasts gradually increased in the blood. We made a diagnosis of acute megakaryoblastic leukemia derived from donor cell with a fluorescence in situ hybridization (FISH) analysis of the sex chromosomes and an immunophenotypic analysis. Azacitidine was administered again and produced a therapeutic effect of stable disease. This case suggests that azacitidine may be a useful therapy for patients with acute megakaryoblastic leukemia in situations in which intensive chemotherapy and transplantation are not indicated.

Cite

CITATION STYLE

APA

Adachi, Y., Yamaguchi, Y., Sagou, K., Yamaga, Y., Fukushima, N., Ozeki, K., & Kohno, A. (2018). Acute megakaryoblastic leukemia developing as donor cell leukemia after umbilical cord blood transplantation. Internal Medicine, 57(4), 569–574. https://doi.org/10.2169/internalmedicine.9005-17

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free